A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells (Cancer Immunology, Immunotherapy DOI: 10.1007/s00262-008-0525-2);A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells

Cancer Immunology, Immunotherapy

Volumn 58, Issue 2, 2009, Pages 301-308

  Wang, Xuelian ^a,b   Santin, Alessandro D ^a   Bellone, Stefania ^a   Gupta, Sushil ^a   Nakagawa, Mayumi ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Dendritic cells (DC); Human papillomavirus (HPV); T cell epitope

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; EPITOPE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DENDRITIC CELL; DOSE RESPONSE; FEMALE; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGY; MOLECULAR GENETICS; PHASE 1 CLINICAL TRIAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UTERINE CERVIX TUMOR;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, CD4; CANCER VACCINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UTERINE CERVICAL NEOPLASMS;

EID: 58149400628     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0617-z     Document Type: Erratum

References (34)

1. HIV HLA Anchor Residue Motif Scan
2. Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg SA, Steller MA (1996) Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 175:1586-1593 (Pubitemid 27021032)
3. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480
4. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego J, Bianchi A, Saiag P, Levy JP, Guillet JG, Choppin J (2000) Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 30:2281-2289
5. Cassell D, Forman J (1988) Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes. Ann N Y Acad Sci 532:51-60 (Pubitemid 19017626)
6. Evans EM, Man S, Evans AS, Borysiewicz LK (1997) Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57:2943-2950 (Pubitemid 27315044)
7. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, Man S (2001) Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 167:5420-5428 (Pubitemid 33009783)
8. Gallagher KM, Man S (2007) Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4 + T cells from healthy young women. J Gen Virol 88:1470-1478 (Pubitemid 46723228)
9. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355
10. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357-2368 (Pubitemid 29028508)
11. Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Muller RT, Jochmus I, Gissmann L, Schneider A, Durst M (2001) HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 92:285-293 (Pubitemid 32225382)
12. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, Njagi E, Irungu E, Farah B, Oyugi J, Chakraborty R, MacDonald KS, Bwayo JJ, McMichael A, Rowland-Jones SL (2001) CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 107:1303-1310 (Pubitemid 32494547)
13. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406-3416
14. Nakagawa M, Kim KH, Moscicki A-B (2004) Different Methods of Identifying New Antigenic Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins. Clin Diagn Lab Immunol 11:889-896 (Pubitemid 39280594)
15. Nakagawa M, Kim KH, Gillam TM, Moscicki A-B (2007) HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol 81:1412-1423 (Pubitemid 46167862)
16. Nakagawa M, Kim KH, Moscicki A-B (2005) Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol 12:1003-1005
17. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki A-B, Palefsky JM (1997) Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 175:927-931 (Pubitemid 27142969)
18. Oerke S, Hohn H, Zehbe I, Pilch H, Schicketanz KH, Hitzler WE, Neukirch C, Freitag K, Maeurer MJ (2005) Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. Int J Cancer 114:766-778 (Pubitemid 40344438)
19. Okubo M, Saito M, Inoku H, Hirata R, Yanagisawa M, Takeda S, Kinoshita K, Maeda H (2004) Analysis of HLA-DRB1*0901-binding HPV-16 E7 helper T cell epitope. J Obstet Gynaecol Res 30:120-129 (Pubitemid 38508627)
20. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693-702 (Pubitemid 28115185)
21. Peng S, Trimble C, Wu L, Pardoll D, Roden R, Hung CF, Wu TC (2007) HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4 + T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 13:2479-2487 (Pubitemid 46698600)
22. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934-5943
23. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, OVringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ (2000) Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255-266 (Pubitemid 30165175)
24. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell. Nature 393:474-478
25. Romerdahl CA, Kripke ML (1988) Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res 48:2325-2328
26. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ (2008) Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82:1968-1979 (Pubitemid 351206942)
27. Schild HJ, Kyewski B, Von Hoegen P, Schirrmacher V (1987) CD4 + helper T cells are required for resistance to a highly metastatic murine tumor. Eur J Immunol 17:1863-1866 (Pubitemid 18052059)
28. Schoenberger SP, Toes RE, van der Voort EI, OVringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483
29. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML (1998) High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10:1593-1598 (Pubitemid 28502373)
30. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, OVringa R (2001) Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91:612-618 (Pubitemid 32115253)
31. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19 (Pubitemid 29406813)
32. Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S (2000) Use of Xuorogenic histocompatibility leukocyte antigen- A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 60:365-371 (Pubitemid 30070764)
33. zur Hausen H (1999) Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol 9:405-411
34. zur Hausen H (1996) Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1288:F55-F78